Premium
P2‐191: Investigating the association between fasting serum glucose levels and cerebral metabolic rate for glucose in brain regions affected by Alzheimer's disease
Author(s) -
Burns Christine,
Chen Kewei,
Kaszniak Alfred,
Lee Wendy,
Alexander Gene,
Bandy Daniel,
Fleisher Adam,
Caselli Richard,
Reiman Eric
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.09.024
Subject(s) - apolipoprotein e , precuneus , dementia , posterior cingulate , medicine , disease , alzheimer's disease , psychology , cognitive decline , fluorodeoxyglucose , positron emission tomography , cognition , endocrinology , neuroscience
months of age, resulting in the development of memory deficits. At 8months of age, Tg2576 mice received unilateral intracerebral injection of either a progranulin-expressing lentiviral vector (ND-602), or a control vector expressing green fluorescent protein (GFP), into the left dorsal hippocampus. At 12 months of age, animals were sacrificed and the brains assessed for pathology.Results:ND-602 was capable of elevating PGRN expression in the dorsal hippocampus, frontal cortex, and entorhinal cortex. Elevations in PGRN expression were associated with increased neprilysin expression, reduced plaque burden, decreased neuroinflammation, and preservation of synapses. Conclusions: Together, the data reported here indicate that ND602 treatment regulates Aß, a key causal factor in AD, by reducing tissue levels in Tg2576 mice as well as plaque deposition. Thus, ND-602, by targeting PGRN,may represent a potential therapy designed to slow or halt disease progression in AD.